Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Total Current Liabilities
All obligations due within one year.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 73.5% from a year ago
Total current liabilities stood at $31.75M at the end of Q1 FY2026, up 73.5% from a year earlier and down 33.3% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.
Context
- Total current liabilities amounted to 22.5% of total assets at the end of Q1 FY2026, up 4.6 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +73.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 47.61M USD
- Year-over-year change
- +152.4%
- 4-year CAGR
- +21.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.61M | +152.4% |
| FY2024 | 2024-12-31 | 18.87M | +3.0% |
| FY2023 | 2023-12-31 | 18.31M | -53.7% |
| FY2022 | 2022-12-31 | 39.53M | +80.0% |
| FY2021 | 2021-12-31 | 21.96M | — |
Total Current Liabilities vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's Mar 2026 total current liabilities of $31.75M is the lowest of the 10 companies compared; the peer median is $135.58M.
- Its year-over-year change of +73.5% is the 2nd highest of 10, against a peer median of +24.7%.
- Total current liabilities amounts to 22.5% of total assets for AQST, versus a peer median of 26.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $651.93M | +37.4% | +3.0% | 14.7% | |
| Mar 2026 | $434.97M | -10.6% | +0.5% | 26.3% | |
| Jun 2026 | $347.38M | +21.3% | -21.1% | 24.3% | |
| Mar 2026 | $164.48M | -17.4% | +18.6% | 10.0% | |
| Mar 2026 | $135.58M | +30.5% | +16.7% | 31.3% | |
| Mar 2026 | $118.59M | +24.7% | +14.2% | 30.3% | |
| Mar 2026 | $47.03M | +74.3% | +48.4% | 16.9% | |
| Mar 2026 | $37.83M | -5.9% | -17.6% | 41.3% | |
| Mar 2026 | $34.49M | +35.1% | +8.7% | 48.6% | |
| Mar 2026 | $31.75M | +73.5% | +6.4% | 22.5% | |
| Peer median (excluding AQST) | $135.58M | +24.7% | +8.7% | 26.3% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.02M | 27.27M | 23.87M | 71.55M | 121.17M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 12.12M | 4.7M | 8.47M | 7.34M | 17.76M |
| Inventory | 4.04M | 5.78M | 6.77M | 6.04M | 6.17M |
| Other Current Assets | 0 | 2.13M | 1.85M | 3.29M | 4.17M |
| Total Current Assets | 47.26M | 39.89M | 40.97M | 88.22M | 149.27M |
| Property, Plant & Equipment (Net) | 7.78M | 9.3M | 9.74M | 8.98M | 8.51M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 51K | 1.44M | 1.28M | 0 | 0 |
| Long-term Investments | 6M | 0 | 4M | 3M | 2M |
| Tax Assets | (6M) | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.9M | 6.45M | 1.44M | 1.22M | 642K |
| Total Non-current Assets | 14.73M | 17.18M | 16.45M | 13.2M | 11.16M |
| Total Assets | 61.99M | 57.07M | 57.42M | 101.42M | 160.43M |
| Account Payables | 8.31M | 9.95M | 8.93M | 10.29M | 29.86M |
| Short-term Debt | 2.03M | 18.7M | 22K | 26K | 11.63M |
| Tax Payables | 349K | 322K | 337K | 365K | 0 |
| Deferred Revenue | 765K | 1.51M | 1.55M | 1.05M | 1.09M |
| Other Current Liabilities | 7.19M | 7.54M | 5.12M | 1M | 1.32M |
| Total Current Liabilities | 21.96M | 39.53M | 18.31M | 18.87M | 47.61M |
| Long-term Debt | 51.55M | 33.45M | 27.51M | 32.5M | 115.48M |
| Deferred Tax Liabilities | 59.06M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 7.12M | 31.42M | 32.35M | 20.01M | 19.39M |
| Other Non-current Liabilities | 2.49M | 66.15M | 80.35M | 85.24M | 7.27M |
| Total Non-current Liabilities | 122.16M | 136.1M | 145.6M | 142.72M | 146.48M |
| Total Liabilities | 144.13M | 175.62M | 163.91M | 161.58M | 194.09M |
| Common Stock | 41K | 55K | 69K | 91K | 122K |
| Retained Earnings | (256.8M) | (311.21M) | (319.08M) | (363.21M) | (447M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (82.13M) | (118.55M) | (106.49M) | (60.16M) | (33.66M) |
| Total Debt | 56.42M | 57.49M | 33.32M | 38M | 131.45M |
| Net Debt | 28.4M | 30.22M | 9.45M | (33.54M) | 10.28M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.